| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S81125-2mg买3赠1 |
99.40% | ￥200.00 |
8 | - | - | - | - |
|
S81125-5mg买3赠1 |
99.40% | ￥300.00 |
6 | - | - | - | - |
|
S81125-10mg买3赠1 |
99.40% | ￥400.00 |
6 | - | - | - | - |
|
S81125-25mg买3赠1 |
99.40% | ￥500.00 |
7 | - | - | - | - |
|
S81125-50mg买3赠1 |
99.40% | ￥700.00 |
7 | - | - | - | - |
|
S81125-100mg买3赠1 |
99.40% | ￥1000.00 |
3 | - | - | - | - |
|
| 产品描述： | Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | JAK2：3 nM (IC50)；JAK2(V617F)：3 nM (IC50)；Flt3：15 nM (IC50)；Ret：48 nM (IC50);Apoptosis; FLT; c-RET; JAK | ||||||||||||||||||||
| 体内研究： | Fedratinib (TG101348; 60-120 mg/kg; oral gavage; twice daily; for 42 days; C57Bl/6 mice) trewatment shows a dose-dependent reduction in polycythemia and a marked dose-dependent reduction in splenomegaly of treated animals | ||||||||||||||||||||
| 参考文献： | 1. Wernig G, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13(4):311-20. 2. Geron I, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008 Apr;13(4):321-30. | ||||||||||||||||||||
| 溶解性： | DMSO : 125 mg/mL (238.24 mM; Need ultrasonic) | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京